File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pediatric ventricular assist device therapy for advanced heart failure-Hong Kong experience

TitlePediatric ventricular assist device therapy for advanced heart failure-Hong Kong experience
Authors
KeywordsVentricular assist device-pediatric
Implantable VAD
Paracorporeal VAD
Transplantation
Issue Date2020
PublisherSpringer Japan. The Journal's web site is located at http://link.springer.de/link/service/journals/10047/index.htm
Citation
Journal of Artificial Organs, 2020, v. 23, p. 133-139 How to Cite?
AbstractVentricular assist devices (VADs) are life-saving options for children with heart failure unresponsive to medical therapy as a bridge to transplantation or cardiac recovery. We present a retrospective review of 13 consecutive children who underwent implantation of VAD between 2001 and 2018 in our center. The median age was 12 years (1–17 years), weight was 45 kg (10–82 kg). Etiologies of heart failure were dilated cardiomyopathy (CMP) (n = 8), myocarditis (n = 2), ischemic CMP (n = 1), restrictive CMP (n = 1) and congenital heart disease (n = 1). Pre-implantation ECMO was used in 5, mechanical ventilation in 4, renal replacement therapy in 2 and IABP in 1. Devices used were: Berlin Heart EXCOR left VAD (LVAD), biventricular VAD (BIVAD) (n = 5, 2), CentriMag LVAD, BIVAD (n = 1, 2), HeartWare (n = 2), HeartMate II (n = 1). Median duration of support was 45 days (3–823 days). Overall survival was 85%. Four patients were successfully bridged to transplantation, 2 died while on a device, 4 remain on support and 3 were weaned from VAD. Late death occurred in 2 transplanted patients. Complications included bleeding requiring reoperation in 1, neurologic events in 3, driveline infections and pericardial effusion in 2 each. In one patient, CentriMag BIVAD provided support for 235 days, which is longest reported duration on such a VAD in the Asia Pacific region. Survival for pediatric patients of all ages is excellent using VADs. Given the severity of illness in these children morbidity and mortality is acceptable. VADs could potentially be used as a long-term bridge to transplantation in view of the donor shortage in the pediatric population.
Persistent Identifierhttp://hdl.handle.net/10722/283417
ISSN
2019 Impact Factor: 1.223
2015 SCImago Journal Rankings: 0.660

 

DC FieldValueLanguage
dc.contributor.authorBhatia, I-
dc.contributor.authorHo, KLC-
dc.contributor.authorRocha, BA-
dc.contributor.authorYam, N-
dc.contributor.authorLun, KS-
dc.contributor.authorYung, TC-
dc.contributor.authorAu, WKT-
dc.date.accessioned2020-06-22T02:56:09Z-
dc.date.available2020-06-22T02:56:09Z-
dc.date.issued2020-
dc.identifier.citationJournal of Artificial Organs, 2020, v. 23, p. 133-139-
dc.identifier.issn1434-7229-
dc.identifier.urihttp://hdl.handle.net/10722/283417-
dc.description.abstractVentricular assist devices (VADs) are life-saving options for children with heart failure unresponsive to medical therapy as a bridge to transplantation or cardiac recovery. We present a retrospective review of 13 consecutive children who underwent implantation of VAD between 2001 and 2018 in our center. The median age was 12 years (1–17 years), weight was 45 kg (10–82 kg). Etiologies of heart failure were dilated cardiomyopathy (CMP) (n = 8), myocarditis (n = 2), ischemic CMP (n = 1), restrictive CMP (n = 1) and congenital heart disease (n = 1). Pre-implantation ECMO was used in 5, mechanical ventilation in 4, renal replacement therapy in 2 and IABP in 1. Devices used were: Berlin Heart EXCOR left VAD (LVAD), biventricular VAD (BIVAD) (n = 5, 2), CentriMag LVAD, BIVAD (n = 1, 2), HeartWare (n = 2), HeartMate II (n = 1). Median duration of support was 45 days (3–823 days). Overall survival was 85%. Four patients were successfully bridged to transplantation, 2 died while on a device, 4 remain on support and 3 were weaned from VAD. Late death occurred in 2 transplanted patients. Complications included bleeding requiring reoperation in 1, neurologic events in 3, driveline infections and pericardial effusion in 2 each. In one patient, CentriMag BIVAD provided support for 235 days, which is longest reported duration on such a VAD in the Asia Pacific region. Survival for pediatric patients of all ages is excellent using VADs. Given the severity of illness in these children morbidity and mortality is acceptable. VADs could potentially be used as a long-term bridge to transplantation in view of the donor shortage in the pediatric population.-
dc.languageeng-
dc.publisherSpringer Japan. The Journal's web site is located at http://link.springer.de/link/service/journals/10047/index.htm-
dc.relation.ispartofJournal of Artificial Organs-
dc.rightsThis is a post-peer-review, pre-copyedit version of an article published in [insert journal title]. The final authenticated version is available online at: https://doi.org/[insert DOI]-
dc.subjectVentricular assist device-pediatric-
dc.subjectImplantable VAD-
dc.subjectParacorporeal VAD-
dc.subjectTransplantation-
dc.titlePediatric ventricular assist device therapy for advanced heart failure-Hong Kong experience-
dc.typeArticle-
dc.identifier.emailLun, KS: lunks@hkucc.hku.hk-
dc.identifier.emailYung, TC: tcyung@hkusua.hku.hk-
dc.identifier.emailAu, WKT: auwkt@hkucc.hku.hk-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s10047-019-01140-4-
dc.identifier.pmid31624968-
dc.identifier.scopuseid_2-s2.0-85076465431-
dc.identifier.hkuros310476-
dc.identifier.volume23-
dc.identifier.spage133-
dc.identifier.epage139-
dc.publisher.placeJapan-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats